Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...

Whether it’s Ozempic, one of the antidiabetic drugs that have gained popularity for its weight loss benefits, or a similar ...

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said.

The Food and Drug Administration today approved Eli Lilly’s weight-loss treatment, Zepbound, for obstructive sleep apnea, ...

The FDA has approved Eli Lillys Zepbound as the first weight-loss drug to treat obstructive sleep apnea, reshaping care for ...

"Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Sally ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 471.82% and ...

The FDA has declared the end of the two-year shortages of Eli Lilly's Mounjaro and Zepbound — used to treat diabetes and weight loss, respectively — and has reaffirmed its decision to halt the ...